Convatec has achieved a key milestone with the U.S. FDA approval of subcutaneous apomorphine infusion for the treatment of advanced Parkinson’s disease, delivered via its Neria™ Guard infusion set. This innovative therapy offers a non-surgical, continuous drug delivery method that helps address the often-debilitating motor fluctuations experienced by Parkinson’s patients. Unlike traditional approaches that may involve invasive procedures, the system combines apomorphine hydrochloride with a small, portable infusion pump and a user-friendly insertion mechanism, offering a less burdensome and more accessible treatment path.
The Neria™ Guard infusion set is designed with safety, simplicity, and patient independence in mind. Its one-touch button technology minimizes human error and enhances ease of use, making it suitable for both home and clinical settings. Already widely used in Europe, the device has proven effective in supporting patients’ daily routines without interfering with quality of life. Its deployment in the U.S. market now offers healthcare providers and patients a much-needed alternative to existing Parkinson’s therapies, particularly for those who are not candidates for surgical interventions or who experience difficulties managing oral medications.
This FDA approval represents not only a win for Convatec but a broader advancement in chronic disease management and patient-centered care. With Parkinson’s disease affecting over a million Americans—and that number projected to rise—accessible, effective therapies are in urgent demand. By enabling more consistent symptom control and reducing reliance on hospital-based treatments, Convatec’s innovation empowers patients to maintain independence and stability in daily living, reinforcing the company’s role as a global leader in infusion care.
MedTech Spectrum's Summary
Non-Surgical Innovation for Parkinson’s Care: Convatec’s FDA-approved subcutaneous apomorphine infusion system, delivered via the Neria™ Guard infusion set, offers a non-invasive alternative for advanced Parkinson’s disease management—enhancing accessibility and reducing treatment complexity.
Patient-Centric Design and Improved Quality of Life: The Neria™ Guard’s one-touch button technology ensures easy, safe, and independent use, promoting greater adherence, reducing human error, and enabling patients to better manage motor symptoms with more 'on' time in daily life.
Expanded Global Impact: Already in use across Europe, the system's U.S. approval marks a major expansion, aligning with the growing need for personalized, flexible treatments in the face of rising Parkinson’s incidence—reinforcing Convatec’s leadership in subcutaneous drug delivery solutions.
